Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease

References

• Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an indepen-dent risk factor for vascular disease. N Engl J Med 1991; 324: 1149–55.
   Google Scholar
• Schnyder G, Roffi M, Flammer Y, Pin R, Eberli FR, Meier B, Turi ZG, Hess OM. Effect of homocysteine-lowering ther-apy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Am J Cardiol 2003; 91: 1265–9.
   Google Scholar
• Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arter-ies. N Engl J Med 1986; 315: 1046–51.
   Google Scholar
• Zeiher AM, Drexler H, Wollschlager H, Just H. Modula-tion of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coro-nary atherosclerosis. Circulation 1991; 83: 391-4.01.
   Google Scholar
• Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mech-anisms. N Engl J Med 1995; 332: 512–21.
   Google Scholar
• Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunc-tion. Circulation 2000; 101: 948–54.
   Google Scholar
• Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801–9.
   Google Scholar
• Vita JA, Yeung AC, Winniford M, Hodgson JM, Treasure CB, Klein JL, Werns S, Kern M, Plotkin D, Shih WJ, Mitchel Y, Ganz P. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000; 102: 846–51.
   Google Scholar
• Mancini GB, Henry GC, Macaya C, O’Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Liischer TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapfil impmves endothe-lial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dys-function) Study. Circulation 1996; 94: 258–65.
   Google Scholar
• Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99: 178–82.
   Google Scholar
• Stamler JS, Osborne JA, Jaraki 0, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocys-teine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308–18.
   Google Scholar
• Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119–21.
   Google Scholar
• Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369–73.
   Google Scholar
• Wall RT, Harlan JM, Harker LA, Striker GE. Homocys-teine-induced endothelial cell injury in vitro: A model for the study of vascular injury. Thromb Res 1980; 18: 113–21.
   Google Scholar
• Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperho-mocyst(e)inemia is a risk factor for arterial endothelial dys-function in humans. Circulation 1997; 96: 2542–4.
   Google Scholar
• Clarke R, Armitage J. Vitamin supplements and cardiovas-cular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost 2000; 26: 341–8.
   Google Scholar
• Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentra-tions of free plasma homocysteine. Circulation 2000; 102: 2479–83.
   Google Scholar
• Dinckal HM, Aksoy N, Aksoy M, Davutoglu V, Soydinc S, Kirilmaz A, Dinckal N, Akdemir I. Effect of homocysteine-lowering therapy on vascular endothelial function and exer-cise performance in coronary patients with hyperhomocys-teinaemia. Acta Cardiol 2003; 58: 389–96.
   Google Scholar
• Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxi-dant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6: 593–7.
   Google Scholar
• Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med 1993; 14: 683–93.
   Google Scholar
• Eklund A, Eriksson (5, Hakansson L, Larsson K, Ohlsson K, Venge P, Bergstrand H, Björnson A, Brattsand R, Glen-now C. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activation in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J 1988; 1: 832–8.
   Google Scholar
• Winyard PG, Blake DR. Antioxidants, redox-regulated tran-scription factors, and inflammation. Adv Pharmacol 1997; 38: 403–21.
   Google Scholar
• Hultberg B, Andersson A, Masson P, Larson M, Tunek A. Plasma homocysteine and thiol compound fractions after oral administration of N-acetylcysteine. Scand J Clin Lab Invest 1994; 54: 417–22.
   Google Scholar
• Ventura P, Panini R, Pasini MC, Scarpetta G, Salvioli G. N-Acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols uri-nary excretion. Pharmacol Res 1999; 40: 345–50.
   Google Scholar
• Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller 01, Sullivan ID Lloyd JK, Deanfield JE. Non-inva-sive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–5.
   Google Scholar
• Chao CL, Chien KL, Lee YT. Effect of short-term vitamin (folic acid, vitamins B6 and B12) administration on endothe-lial dysfunction induced by post-methionine load hyperho-mocysteinemia. Am J Cardiol 1999; 84: 1359–61.
   Google Scholar
• Guo H, Lee JD, Xing Y, Cheng J, Ueda T, Toyoda K, Geshi T. Changes of homocysteine levels and arterial endothelial function in patients with high risk of coronary artery disease after 6-month folic acid supplementation. Acta Cardiol 2004; 59: 503–6.
   Google Scholar
• Thambyrajah J, Landray MJ, Jones HJ, McGlynn FJ, Wheeler DC, Townend JN. A randomized double-blind placebo-controlled trial of the effect of homocysteine-low-ering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol 2001; 37: 1858–63.
   Google Scholar
• Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcys-teine in fibrosing alveolitis. Adjunctive therapy to mainte-nance immunosuppression. Am J Respir Crit Care Med 1997; 156: 1897–1901.
   Google Scholar
• Meyer A, Buhl R, Magnussen H. The effect of oral N-acetyl-cysteine on lung glutathione of patients with pulmonary fibrosis. Eur Respir J 1994; 7: 431–6.
   Google Scholar
• Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 1996; 54: 1–30.
   Google Scholar
• Wiklund 0, Fager G, Andersson A, Lundstam U, Masson P, Hultberg B. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. Athero-sclerosis 1996; 119: 99–106.
   Google Scholar
• Bostom AG, Shemin D, Yoburn D, Fisher DH, Nadeau MR, Selhub J. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis 1996; 120: 241–4.
   Google Scholar
• Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004; 109: 369–74.
   Google Scholar
• Miner SE, Cole DE, Evrovs.ki J, Forrest Q, Hutchison SJ, Holmes K, Ross HJ. N-acetylcysteine neither lowers plasma homocysteine concentrations nor improves brachial artery endothelial function in cardiac transplant recipients. Can J Cardiol 2002; 18: 503–7.
   Google Scholar
• Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol 2001; 37: 117–23.
   Google Scholar
• Roes EM, Raijmakers MT, Peters WH, Steegers EA. Effects of oral N-acetylcysteine on plasma homocysteine and whole blood glutathione levels in healthy, non-pregnant women. Clin Chem Lab Med 2002; 40: 496–8.
   Google Scholar
• Kang SS, Wong PW, Cook HY, Norusis M, Messer JV. Pro-tein-bound homocyst(e)ine. A possible risk factor of coro-nary disease. J Clin Invest 1986; 77: 1482–6.
   Google Scholar